Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Florian Oberndörfer"'
Autor:
Svenja Vanessa Wiedemann, Verena Müller, Bettina Toth, Michael Erdmann, Bodo Bühler, Susanne Dugas-Breit, Kerstin Schatton, Lydia Reinhardt, Markus Meissner, Marion Mickler, Claudia Pföhler, Carsten Weishaupt, Rudolf Herbst, Dirk Debus, Laura Susok, Julia Katharina Tietze, Julia Welzel, Andreas Arnold, Evelyn Dabrowski, Andrea Forschner, Steven Goetze, Kinan Hayani, Céleste Lebbe, Florian Löhr, Miriam Mengoni, Barbara Hermes, Wiebke Katharina Peitsch, Gabriela Poch, Michael Sachse, Anca Sindrilaru, Saskia Wenk, Mirjana Ziemer, Kjell Kaune, Lisette Meier-Naust, Georgios Nikolakis, Florian Oberndörfer, Ulrich Wesselmann, Jochen Utikal, Maria Rita Gaiser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48aa19913f5c8ce528ef919115416a35
https://doi.org/10.2139/ssrn.4432467
https://doi.org/10.2139/ssrn.4432467
Autor:
Carsten Weishaupt, Vesna Alar, Sebastian Haferkamp, Ralf Gutzmer, Jürgen C. Becker, Imke Satzger, Selma Ugurel, Yenny Angela, Florian Oberndörfer
Publikováno v:
Cancer Immunology, Immunotherapy. 68:1187-1194
PD-1 inhibition (PD-1i) is the standard of care in melanoma and other malignancies. In patients with bone metastases of solid tumors, the monoclonal antibody denosumab directed against RANKL is approved for the prevention of skeletal-related events.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::291532c28efefa473108a1bb038c1b49
https://doi.org/10.1007/s00262-019-02353-5
https://doi.org/10.1007/s00262-019-02353-5
